$VERU

VERU INC.

Veru is a biopharmaceutical company focused on developing medicines for cardiometabolic and inflammatory diseases. Its drug development portfolio includes enobosarm, an oral selective androgen receptor modulator being developed to preserve muscle and physical function and increase fat loss in people with obesity receiving GLP-1 receptor agonists, and sabizabulin, an oral microtubule disruptor being explored to treat inflammation associated with atherosclerotic cardiovascular disease. Veru plans clinical studies of both candidates, including a Phase 2b study of enobosarm and a Phase 2 study of sabizabulin. Veru’s current business focuses on developing drug candidates for potential commercialization. It sold its FC2 female condom business, which included the FC2 Female Condom (Internal Condom), on December 30, 2024. Veru is headquartered in Miami, Florida.

2
0
0

No SEC Form 4 filings for $VERU in the last 30 days.

See all $VERU insider activity →
Med

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

VERU sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning VERU (VERU INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent VERU coverage spans earnings, technology and financial news.

What's driving VERU

  • Conference post hoc results improve the functional and body-composition narrative for enobosarm plus semaglutide, potentially supporting trial momentum ahead of later interim and final readouts.

    investing.com · Nov 17, 2026

  • New clinical‑trial data could shift market expectations for Veru's obesity program.

    investing.com · Nov 9, 2026

  • Analyst reaffirmation boosts sentiment and may attract buying ahead of upcoming trial data.

    investing.com · Oct 14, 2026

  • Analyst upgrade may lift the stock if trial data are positive.

    investing.com · Oct 14, 2026

  • Positive preclinical results could boost investor confidence and drive near‑term share price appreciation as the company advances toward a pivotal trial.

    SEC EDGAR 8-K · Sep 8, 2026

AlphAI scores every news story that mentions VERU with an AI model for sentiment and relevance, and aggregates insider trades from VERU INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VERU

Score

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$VERUMedAI 8/10

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

$VERUHighAI 8/10Clinical / regulatory· trial start

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…

VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib

$VERUMedEarnings

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

VERU INC. (VERU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress — Phase 2b PLATEAU cl

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru Inc. (NASDAQ: VERU) said it will present at the 2026 Obesity & Weight Loss Drug Development Summit in Boston (July 14–16, 2026). The company’s CEO Mitchell Steiner will discuss combining GLP-1s with SARMs to address sarcopenic obesity. Veru also outlined its Phase 2b PLATEAU enobosarm+semaglutide study (about 200 older patients), with interim analysis expected at 32 weeks in 1Q 2027 and topline data in 4Q 2027.

Related tickers